Autologous stem cell rescue for newly diagnosed brain tumor
Treatments studied
Part of Cancer clinical trials.
This trial tests giving a patient’s own stem cells back to help the bone marrow recover after treatment for newly diagnosed glioblastoma or gliosarcoma. It may help reduce blood-count problems so treatment can be given more safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 to 75 years old, with a newly diagnosed glioblastoma or gliosarcoma in the brain area above the cerebellum.
- Your surgery removed most of the tumor (over 85% of enhancing tumor), and you have limited leftover visible disease.
- Your tumor lab tests show MGMT is unmethylated, and your tumor has no IDH1 or IDH2 mutation.
- You can start the study within 35 days after surgery and are stable enough for the trial plan, including MRI follow-ups.
- You must have enough blood, liver, and kidney function based on recent lab tests, and steroids (if used) must be reduced and stable.
- There must be no active infection, and you must test negative for HIV, hepatitis B, and hepatitis C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a personalized immune-cell treatment (CAR-T) made from your own cells to attack a marker called B7-H3 on recurring glioblastoma. It may help shrink or control the tumor, but the main goal is to check safety and how the treatment works.
This Phase 1 trial tests a gene-edited immune cell treatment given into the brain to treat recurrent (returning) grade 4 glioblastoma or related tumors. It aims to find a safe dose and see whether the treatment can slow tumor growth.
This early study tests whether a device called TheraSphere is safe when delivered into the brain to treat recurrent glioblastoma. It may help patients by trying a targeted treatment approach, while doctors carefully monitor side effects and safety.
This trial is testing whether a drug called G-CSF (which helps boost white blood cells) can help people with glioblastoma who are already receiving standard treatment with radiation and chemotherapy (temozolomide). It aims to see if G-CSF can reduce side effects and improve outcomes.
This Phase 3 trial tests whether adding a patient-specific immune cell treatment (made from your blood) after surgery and standard radiation plus temozolomide (RT/TMZ) can help people with newly diagnosed glioblastoma (GBM). It’s designed to see if the added therapy improves outcomes compared with standard treatment alone.
This early trial tries to find which medicines might work best for your specific glioblastoma, by testing drugs on cancer “stem cell” samples. If the test finds promising drug options, it may guide a more personalized treatment approach.
Hear when a new Glioblastoma Multiforme trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.